Results of meta-analyses excluding and including results from preprints, by mechanical ventilation outcome
| Drug treatment duration | Meta-analyses excluding unpublished preprints | Meta-analyses including all preprints | ||||
| No of studies (participants) | Risk difference with standard care/placebo (95% CI; per 1000 people) | GRADE assessment for certainty of evidence | No of studies (participants) | Risk difference with standard care/placebo (95% CI; per 1000 people) | GRADE assessment for certainty of evidence | |
| Mechanical Ventilation | ||||||
| Corticosteroids | ||||||
| 1 month | 1 (5418) | 43 fewer (59.24 fewer to 22.12 fewer) | Moderate | 2 (5472) | 1.2 more (60.3 fewer to 131.1 more) | Very low |
| 3 months | 5 (6324) | 32.56 fewer (44.16 fewer to 19.8 fewer) | Moderate | 6 (6378) | 17.4 fewer (29 fewer to 3.5 fewer) | Moderate |
| 6 months | 5 (6324) | 32.56 fewer (44.16 fewer to 19.8 fewer) | Moderate | 6 (6378) | 17.4 fewer (29 fewer to 3.5 fewer) | Moderate |
| Current | 9 (6576) | 27.92 fewer (39.52 fewer to 15.16 fewer) | Moderate | 9 (6576) | 13.9 fewer (25.5 fewer to 1.2 fewer) | Moderate |
| Remdesivir | ||||||
| 1 month | 2 (1001) | 47.6 fewer (65 fewer to 24.4 fewer) | High | 2 (1001) | 47.6 fewer (65 fewer to 24.4 fewer) | High |
| 3 months | 2 (1001) | 47.6 fewer (65 fewer to 24.4 fewer) | High | 2 (1001) | 47.6 fewer (65 fewer to 24.4 fewer) | High |
| 6 months | 3 (1585) | 51 fewer (67.3 fewer to 30.2 fewer) | High | 4 (6549) | 39.4 fewer (68.4 fewer to 8.1 more) | Low |
| Current | 5 (6619) | 32.5 fewer (62.6 fewer to 13.9 more) | Low | 6 (7451) | 27.8 fewer (52.2 fewer to 4.6 more) | Low |
| Lopinavir-ritonavir | ||||||
| 1 month | 1 (198) | 30.2 fewer (71.9 fewer to 48.7 more) | Very low | 1 (198) | 30.2 fewer (71.9 fewer to 48.7 more) | Very low |
| 3 months | 1 (198) | 30.2 fewer (71.9 fewer to 48.7 more) | Very low | 1 (198) | 30.2 fewer (71.9 fewer to 48.7 more) | Very low |
| 6 months | 1 (198) | 30.2 fewer (71.9 fewer to 48.7 more) | Very low | 1 (198) | 30.2 fewer (71.9 fewer to 48.7 more) | Very low |
| Current | 5 (8474) | 16.2 more (2.3 fewer to 30.2 more) | Low | 5 (8474) | 16.2 more (2.3 fewer to 30.2 more) | Low |
| (Hydroxy)chloroquine (treatment) | ||||||
| 1 month | 2 (642) | 16.2 more (45.2 fewer to 129.9 more) | Very low | 4 (4616) | 17.4 more (7.0 fewer to 45.2 more) | Low |
| 3 months | 4 (4693) | 19.7 more (4.6 fewer to 46.4 more) | Low | 6 (6430) | 17.4 more (3.5 fewer to 40.6 more) | Low |
| 6 months | 7 (6877) | 15.1 more (4.6 fewer to 37.1 more) | Low | 9 (7417) | 12.8 more (4.6 fewer to 33.6 more) | Low |
| Current | 12 (8053) | 26.7 more (5.8 more to 53.4 more) | Moderate | 12 (8053) | 26.7 more (5.8 more to 53.4 more) | Moderate |
| Ivermectin | ||||||
| 1 month | 1 (45) | NA | NA | 2 (90) | 60.3 more (107.9 fewer to 496.5 more) | Very low |
| 3 months | 1 (45) | NA | NA | 4 (354) | 69.6 fewer (109 fewer to 169.4 more) | Very low |
| 6 months | 4 (642) | 2.3 fewer (52.2 fewer to 83.5 more) | Low | 7 (951) | 26.7 fewer (74.2 fewer to 75.4 more) | Very low |
| Current | 8 (1464) | 7.0 fewer (48.7 fewer to 61.5 more) | Low | 9 (1616) | 7.0 fewer (48.7 fewer to 61.5 more) | Low |
| Interleukin six receptor blockers | ||||||
| 1 month | 0 (0) | NA | NA | 1 (273) | 27.8 fewer (54.5 fewer to 10.4 more) | Low |
| 3 months | 3 (495) | 37.1 fewer (66.1 fewer to 10.4 more) | Low | 5 (1145) | 33.6 fewer (52.2 fewer to 8.1 fewer) | Moderate |
| 6 months | 7 (1826) | 30.2 fewer (42.9 fewer to 16.2 fewer) | Moderate | 9 (4000) | 20.9 fewer (31.3 fewer to 8.1 fewer) | Moderate |
| Current | 10 (4170) | 19.7 fewer (30.2 fewer to 8.1 fewer) | Moderate | 12 (4560) | 19.7 fewer (30.2 fewer to 9.3 fewer) | Moderate |
| Convalescent plasma | ||||||
| 1 month | 1 (464) | 9.3 more (47.6 fewer to 104.4 more) | Very low | 3 (705) | 19.7 fewer (70.8 fewer to 90.5 more) | Very low |
| 3 months | 3 (827) | 16.2 more (22 fewer to 70.8 more) | Very low | 6 (1108) | 4.6 more (29 fewer to 48.7 more) | Very low |
| 6 months | 4 (987) | 12.8 more (24.4 fewer to 62.6 more) | Very low | 6 (1108) | 4.6 more (29 fewer to 48.7 more) | Very low |
| Current | 8 (8252) | 2.3 fewer (11.6 fewer to seven more) | Moderate | 9 (8333) | 2.3 fewer (11.6 fewer to 5.8 more) | Moderate |
GRADE=grading of recommendations assessment, development, and evaluation; NA=not available.